AutoSynVax vaccine

Drug Profile

AutoSynVax vaccine

Alternative Names: AutoSynVax™; Neoantigen vaccine - Agenus

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PhosImmune; Pure MHC
  • Developer Agenus
  • Class Cancer vaccines; Heat shock proteins; Monoclonal antibodies; Peptide vaccines; Peptides; Synthetic vaccines
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 04 May 2017 Agenus completes enrolment in its phase I trial for Cancer in USA
  • 01 Jan 2017 Phase-I clinical trials in Cancer in USA (SC) (NCT02992977)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top